Corcept Insider Transaction Explained After Shares Tumble 50% in One Day

Corcept Therapeutics CDO William Guyer exercised and immediately sold 20,000 option-derived shares for about $703,656 (open-market), leaving him with 1,235 direct shares (≈$44,188) and options underlying 250,000 shares. The stock trades at $35.18 with a $3.94B market cap; near-term fundamentals show TTM revenue $741.17M and net income $106.11M, with Q3 revenue of $207.6M and management reaffirming full-year guidance of $800M–$850M and $524M cash. The sale was an option exercise-driven liquidity event rather than an indicated change in outlook, though the company faces regulatory uncertainty after an FDA complete response letter for relacorilant that precipitated a recent price collapse.

Analysis

Market structure: The 20,000-share exercise/sale (~$704k) is immaterial versus CORT’s $3.94B market cap and likely reflects option-liquidity/tax mechanics rather than newly negative information; primary winners are holders of Korlym revenue (CORT) if label/usage holds, while small biotech competitors targeting cortisol pathways face unchanged competition. Pricing power for Korlym remains intact given $207.6M quarter and reaffirmed $800–$850M guidance; supply/demand for float is unchanged absent large insider cascade—expect idiosyncratic equity volatility, not systemic market moves. Cross-asset: a regulatory shock would widen small-cap biotech credit spreads and implied vols (XBI vols), so expect short-term pressure in high-beta biotech equities and option markets; FX/commodities unaffected.

Risk assessment: Tail risks include a final regulatory rejection for relacorilant (binary downside >30–50%), material litigation, or faster-than-expected revenue erosion if prescriptions fall >10% quarter-over-quarter. Immediate (days): elevated IV and choppy price action; short-term (weeks–months): outcomes tied to FDA communications and potential resubmission; long-term (quarters–years): binary payoff from relacorilant approval or program termination. Hidden dependencies: management’s heavy derivative compensation creates potential for future option-related selling if hedges unwind; catalysts: FDA docket updates (30–90d), earnings cadence, IQVIA prescription data weekly.

Trade implications: Tactical trades should size for binary risk. Direct: initiate a small 1–3% long CORT position on dips <$30 (≈15% down) with 20% stop; hedge by buying a 90-day 30/25 put spread sized to cover 50% of notional. Volatility: consider selling short-dated (30–45d) premium if IV spikes after news, and buy LEAP calls (12–18 months) on confirmed resubmission acceptance. Pair trade: go long CORT equity vs short 0.5x XBI to isolate idiosyncratic upside while cutting biotech beta.

Contrarian angles: The market may be over-penalizing a single CRL despite $524M cash and $741M TTM revenue; historical parallels show many biotechs recover post-resubmission when cash runway >1 year. Consensus underweights Korlym’s recurring revenue stream; mispricing exists if CORT trades <3.0x revenue (current ~5.3x). Key unintended risk: insider option hedging could mechanically create additional selling into rallies—monitor Form 4 activity closely.

Key Decisions for Investors

• Establish a tactical 2% long position in CORT (ticker: CORT) on a pullback to <$30 (≈15% below $35.18); set a hard stop-loss at 20% below entry and plan to hold 12–18 months, adding half the position on FDA resubmission acceptance or positive trial readout.
• Buy a 90-day put spread to hedge downside: buy CORT 30-strike put and sell 25-strike put (size to cover 50% of equity notional); if cost >2% of portfolio risk budget, reduce spread size. Close spread on material positive regulatory news or at expiration.
• Implement a relative-value pair: long CORT equity vs short XBI at 0.5x notional (rebalance monthly) to capture idiosyncratic recovery while hedging sector beta; cut pair if CORT underperforms XBI by >25% over 60 days.
• Monitor and act on precise catalysts: (1) Company 8-Ks and FDA communications daily for 90 days, (2) weekly IQVIA Korlym prescription trend data—if month-over-month prescriptions fall >10% or cash falls below $400M, reduce exposure to zero; if resubmission accepted within 60 days, increase CORT position to 4%.